Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial

BACKGROUND: Pneumococcal diseases among children aged <5 years worldwide are associated with high annual mortality rates. PURPOSE: This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 boo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Jonghoon, Teeratakulpisarn, Jamaree, Puthanakit, Thanyawee, Theerawit, Tuangtip, Ryu, Ji Hwa, Shin, Jinhwan, Lee, Seulgi, Lee, Hayoung, An, Kyungjun, Kim, Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Pediatric Society 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374005/
https://www.ncbi.nlm.nih.gov/pubmed/32024323
http://dx.doi.org/10.3345/cep.2019.01067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374005/
https://www.ncbi.nlm.nih.gov/pubmed/32024323
http://dx.doi.org/10.3345/cep.2019.01067

Ejemplares similares